Log in to save to my catalogue

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the doubl...

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the doubl...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2651692888

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

CDKL5 deficiency disorder (CDD) is a rare, X-linked, developmental and epileptic encephalopathy characterised by severe global developmental impairment and seizures that can begin in the first few months after birth and are often treatment refractory. Ganaxolone, an investigational neuroactive steroid, reduced seizure frequency in an open-label, ph...

Alternative Titles

Full title

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2651692888

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2651692888

Other Identifiers

ISSN

1474-4422,1474-4465

E-ISSN

1474-4465

DOI

10.1016/S1474-4422(22)00077-1

How to access this item